We found a potential marker in most cases, showing a strict concordance with TR based MRD methodology (Figure 1), even in non-ETP-ALL with FLT3-ITD (Supplementary Materials—Table S3). This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.